

colorectal cancer | Research | Treatment | 10 pages | source: International Journal of Colorectal Disease | Added Feb 28, 2021
How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?
This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome.


colorectal cancer | Research | Treatment | 10 pages | source: The Lancet. Oncology | Added Feb 26, 2021
Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer
This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity.

colorectal cancer | Research | 10 pages | source: Colorectal Disease | Added Jan 27, 2021
What factors can influence ileostomy closure time after colorectal surgery?
This study evaluated reasons for a delay to ileostomy closure in patients who underwent anterior resection for rectal cancer. This study showed that factors such as having chemotherapy or cancer progression may delay ileostomy closure.


colorectal cancer | Research | Treatment | 10 pages | source: The Oncologist | Added Jan 24, 2021
FOLFOXIRI-bevacizumab or FOLFOX-panitumumab for the treatment of left-sided metastatic colorectal cancer without RAS/BRAF mutations.
This study compared the use of chemotherapy and bevacizumab (Avastin) or panitumumab (Vectibix) for the treatment of left-sided metastatic colorectal cancer (mCRC) without BRAF/RAS mutations (permanent changes in genes). The study found that both treatment options are effective for these patients.


colorectal cancer | Research | Treatment | 10 pages | source: Clinical Colorectal Cancer | Added Jan 19, 2021
Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting
This article looked at the effectiveness of bevacizumab (Avastin) with chemotherapy for metastatic colorectal cancer (mCRC) in a real-world setting. The authors found that the addition of bevacizumab to chemotherapy regimens provides survival benefits in patients who cannot undergo curative local treatment.


colorectal cancer | Research | Treatment | 10 pages | source: The New England Journal of Medicine | Added Jan 15, 2021
Pembrolizumab as a treatment for advanced colorectal cancer predisposed to mutations.
This study compared the use of pembrolizumab (Keytruda) to chemotherapy for the treatment of patients with colorectal cancer (CRC) and high microsatellite instability (MI). This study showed that patients who received pembrolizumab had a better outcome than those who were given chemotherapy.


colorectal cancer | Research | Treatment | 10 pages | source: Clinical Colorectal Cancer | Added Jan 13, 2021
Colorectal cancer treatment with regorafenib and trifluridine/tipiracil: A comparison
This study compared the effectiveness of regorafenib (Stivarga), trifluridine/tipiracil (TFTP; Lonsurf), and combinations of these drugs in the treatment of patients with inoperable colorectal cancer. Researchers suggested that a combination of TFTP and regorafenib is associated with longer survival and fewer side effects.


colorectal cancer | Research | Treatment | 10 pages | source: Annals of Surgery | Added Jan 01, 2021
Liver partition and portal vein ligation improves long-term outcomes of patients with colorectal cancer and liver metastases
This study investigated the long-term outcomes of patients with colorectal cancer (CRC) and liver metastases (LM; cancer spread to the liver) undergoing the ALPPS (associating liver partition and portal vein ligation) procedure. Researchers suggested that patients with LM that were unfit for surgical removal achieved positive long-term outcomes and reduced mortality with this procedure.


colorectal cancer | Research | Treatment | 10 pages | source: Cancer Medicine | Added Dec 30, 2020
What is the optimal timing of surgery for liver metastasis after chemotherapy in patients with colorectal cancer?
The study evaluated the optimal timing of surgery for colorectal cancer liver metastasis (CRLM) after chemotherapy (CT). The main finding was that surgery within 5 weeks after CT may improve patients' outcomes.


colorectal cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Dec 22, 2020
Bevacizumab plus chemotherapy and deep electro-hyperthermia improves the outcomes of patients with advanced colon cancer
This study investigated the effectiveness of bevacizumab plus chemotherapy and deep electro-hyperthermia (DEH) for advanced colon cancer (CC). Researchers suggested that this treatment improves the outcomes of these patients.